The efficiency of genetically modified mesenchymal stromal cells combined with a functionally graded scaffold for bone regeneration in corticosteroid-induced osteonecrosis of the femoral head in rabbits
© 2023 Wiley Periodicals LLC..
Core decompression (CD) with mesenchymal stromal cells (MSCs) is an effective therapy for early-stage osteonecrosis of the femoral head (ONFH). Preconditioning of MSCs, using inflammatory mediators, is widely used in immunology and various cell therapies. We developed a three-dimensional printed functionally graded scaffold (FGS), made of β-TCP and PCL, for cell delivery at a specific location. The present study examined the efficacy of CD treatments with genetically modified (GM) MSCs over-expressing PDGF-BB (PDGF-MSCs) or GM MSCs co-over-expressing IL-4 and PDGF-BB and preconditioned for three days of exposure to lipopolysaccharide and tumor necrosis factor-alpha (IL-4-PDGF-pMSCs) using the FGS for treating steroid-induced ONFH in rabbits. We compared CD without cell-therapy, with IL-4-PDGF-pMSCs alone, and with FGS loaded with PDGF-MSCs or IL-4-PDGF-pMSCs. For the area inside the CD, the bone volume in the CD alone was higher than in both FGS groups. The IL-4-PDGF-pMSCs alone and FGS + PDGF-MSCs reduced the occurrence of empty lacunae and improved osteoclastogenesis. There was no significant difference in angiogenesis among the four groups. The combined effect of GM MSCs or pMSCs and the FGS was not superior to the effect of each alone. To establish an important adjunctive therapy for CD for early ONFH in the future, it is necessary and essential to develop an FGS that delivers biologics appropriately and provides structural and mechanical support.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:111 |
|---|---|
| Enthalten in: |
Journal of biomedical materials research. Part A - 111(2023), 8 vom: 05. Aug., Seite 1120-1134 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tsubosaka, Masanori [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 20.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jbm.a.37495 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351174842 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351174842 | ||
| 003 | DE-627 | ||
| 005 | 20231226050722.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jbm.a.37495 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1170.xml |
| 035 | |a (DE-627)NLM351174842 | ||
| 035 | |a (NLM)36606330 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tsubosaka, Masanori |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The efficiency of genetically modified mesenchymal stromal cells combined with a functionally graded scaffold for bone regeneration in corticosteroid-induced osteonecrosis of the femoral head in rabbits |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 20.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley Periodicals LLC. | ||
| 520 | |a Core decompression (CD) with mesenchymal stromal cells (MSCs) is an effective therapy for early-stage osteonecrosis of the femoral head (ONFH). Preconditioning of MSCs, using inflammatory mediators, is widely used in immunology and various cell therapies. We developed a three-dimensional printed functionally graded scaffold (FGS), made of β-TCP and PCL, for cell delivery at a specific location. The present study examined the efficacy of CD treatments with genetically modified (GM) MSCs over-expressing PDGF-BB (PDGF-MSCs) or GM MSCs co-over-expressing IL-4 and PDGF-BB and preconditioned for three days of exposure to lipopolysaccharide and tumor necrosis factor-alpha (IL-4-PDGF-pMSCs) using the FGS for treating steroid-induced ONFH in rabbits. We compared CD without cell-therapy, with IL-4-PDGF-pMSCs alone, and with FGS loaded with PDGF-MSCs or IL-4-PDGF-pMSCs. For the area inside the CD, the bone volume in the CD alone was higher than in both FGS groups. The IL-4-PDGF-pMSCs alone and FGS + PDGF-MSCs reduced the occurrence of empty lacunae and improved osteoclastogenesis. There was no significant difference in angiogenesis among the four groups. The combined effect of GM MSCs or pMSCs and the FGS was not superior to the effect of each alone. To establish an important adjunctive therapy for CD for early ONFH in the future, it is necessary and essential to develop an FGS that delivers biologics appropriately and provides structural and mechanical support | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a core decompression | |
| 650 | 4 | |a functionally graded scaffold | |
| 650 | 4 | |a genetically modified | |
| 650 | 4 | |a mesenchymal stromal cell | |
| 650 | 4 | |a osteonecrosis | |
| 650 | 7 | |a Becaplermin |2 NLM | |
| 650 | 7 | |a 1B56C968OA |2 NLM | |
| 650 | 7 | |a Interleukin-4 |2 NLM | |
| 650 | 7 | |a 207137-56-2 |2 NLM | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 700 | 1 | |a Maruyama, Masahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Lui, Elaine |e verfasserin |4 aut | |
| 700 | 1 | |a Moeinzadeh, Seyedsina |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Elijah Ejun |e verfasserin |4 aut | |
| 700 | 1 | |a Kushioka, Junichi |e verfasserin |4 aut | |
| 700 | 1 | |a Hirata, Hirohito |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Charu |e verfasserin |4 aut | |
| 700 | 1 | |a Storaci, Hunter W |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Calvin |e verfasserin |4 aut | |
| 700 | 1 | |a Toya, Masakazu |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Teissier, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Huaishuang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xueping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Ning |e verfasserin |4 aut | |
| 700 | 1 | |a Matsumoto, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kuroda, Ryosuke |e verfasserin |4 aut | |
| 700 | 1 | |a Goodman, Stuart B |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yunzhi Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biomedical materials research. Part A |d 2003 |g 111(2023), 8 vom: 05. Aug., Seite 1120-1134 |w (DE-627)NLM12267751X |x 1552-4965 |7 nnns |
| 773 | 1 | 8 | |g volume:111 |g year:2023 |g number:8 |g day:05 |g month:08 |g pages:1120-1134 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jbm.a.37495 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 111 |j 2023 |e 8 |b 05 |c 08 |h 1120-1134 | ||